{"metadata": {"page_hash": "7663012269367129e195bdc3ff39fe813b60a2188b7b602ff265d2202bbd728b", "original_filename": "0000014272-20-000082_20200224x10k.pdf", "page_no": 21, "num_pages": 128, "original_width": 595, "original_height": 842, "coco_width": 1025, "coco_height": 1025, "collection": "sec_filings", "doc_category": "financial_reports"}, "form": [{"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 0, "box_line": [24.738352605042017, 35.57627701900242, 67.05572567226892, 10.713538598574814], "text": "Increased", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 1, "box_line": [103.66294605042017, 35.57627701900242, 52.15444621848741, 10.713538598574814], "text": "pricing", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 2, "box_line": [167.68625831932775, 35.57627701900242, 59.6050799159664, 10.713538598574814], "text": "pressure", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 3, "box_line": [239.1602180672269, 35.57627701900242, 22.351907983193286, 10.713538598574814], "text": "and", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 4, "box_line": [273.38100588235295, 35.57627701900242, 37.25316848739493, 10.713538598574814], "text": "other", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 5, "box_line": [322.50303697478995, 35.57627701900242, 89.40763193277309, 10.713538598574814], "text": "restrictions", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 6, "box_line": [423.77954873949585, 35.57627701900242, 14.901243277310925, 10.713538598574814], "text": "in", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 7, "box_line": [450.549637394958, 35.57627701900242, 22.351959663865614, 10.713538598574814], "text": "the", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 8, "box_line": [484.77042521008406, 35.57627701900242, 23.55891008403364, 10.713538598574814], "text": "U.S.", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 9, "box_line": [520.1982151260505, 35.57627701900242, 22.3519079831932, 10.713538598574814], "text": "and", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 10, "box_line": [554.4190029411765, 35.57627701900242, 44.703798739495824, 10.713538598574814], "text": "abroad", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 11, "box_line": [610.991681512605, 35.57627701900242, 29.80255546218484, 10.713538598574814], "text": "from", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 12, "box_line": [652.6630651260505, 35.57627701900242, 30.28683781512609, 10.713538598574814], "text": "MCOs,", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 13, "box_line": [694.8187827731092, 35.57627701900242, 96.85826218487409, 10.713538598574814], "text": "institutional", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 14, "box_line": [803.545924789916, 35.57627701900242, 74.50635420168078, 10.713538598574814], "text": "purchasers", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 15, "box_line": [889.9211588235295, 35.57627701900242, 22.35183907563021, 10.713538598574814], "text": "and", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 16, "box_line": [924.1419294117647, 35.57627701900242, 74.50630252100848, 10.713538598574814], "text": "government", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053841, "box": [24.738352605042017, 35.57627701900242, 973.9098793277312, 21.938262470308814], "id_box_line": 17, "box_line": [24.738352605042017, 46.801000890736304, 736.3463356302522, 10.713538598574928], "text": "agencies and programs, among others, continue to negatively affect our revenues and profit margins.", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 18, "box_line": [24.738352605042017, 58.12320932304044, 973.9114642016807, 10.616066211401403], "text": "Our products continue to be subject to increasing pressures across the portfolio from market access, pharmaceutical pricing controls and", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 19, "box_line": [24.738352605042017, 69.34794536817105, 973.9166150420169, 10.61605403800479], "text": "discounting and other restrictions in the U.S., the EU and other regions around the world that result in lower prices, lower reimbursement rates", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 20, "box_line": [24.738352605042017, 80.57266923990505, 973.9170457142858, 10.616054038004677], "text": "and smaller populations for whom payers will reimburse, which negatively impact our revenues and profit margins, including from (i) the impact of", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 21, "box_line": [24.738352605042017, 91.79739311163894, 973.9014726050422, 10.616066211401517], "text": "the increased pricing pressure from Medicare Part D formularies, Medicare Part B reimbursement rates (including the potential implementation of", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 22, "box_line": [24.738352605042017, 103.02212915676967, 973.9010591596639, 10.616054038004677], "text": "the pilot program by the Centers for Medicare & Medicaid Services (\u201cCMS\u201d) that would, among other things, set payment amounts to physicians on", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 23, "box_line": [24.738352605042017, 114.24685302850355, 973.9147200840337, 10.61605403800479], "text": "Part B drugs based on international drug prices and would include fifty percent of Medicare Part B single source drugs), expanded utilization under", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 24, "box_line": [24.738352605042017, 125.47157690023755, 973.8959083193279, 10.616066211401403], "text": "the 340B Drug Pricing Program (\u201c340B\u201d), as well as commercial formularies in general; (ii) rules and practices of MCOs and institutional and", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 25, "box_line": [24.738352605042017, 136.69631294536816, 973.9124116806724, 10.61605403800479], "text": "governmental purchasers taking actions to control costs or shift the cost burden to manufacturers, including actions that could result in the", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 26, "box_line": [24.738352605042017, 147.92103681710216, 973.9011625210086, 10.61605403800479], "text": "exclusion of a product from, or the unfavorable placement of, a product on a MCO formulary; (iii) government administrative and policy changes", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 27, "box_line": [24.738352605042017, 159.14576068883616, 973.9111541176471, 10.61605403800479], "text": "and changes in laws and regulations for federal healthcare programs such as Medicare and Medicaid, other government actions and inquiries at", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 28, "box_line": [24.738352605042017, 170.37048456057016, 401.81569025210086, 10.61606621140129], "text": "the federal level (including the proposals contained in the ", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 29, "box_line": [428.84087815126054, 170.37048456057016, 6.5949361344537465, 10.61606621140129], "text": "\u201c", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QOJBAA+DejaVuSerif", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 30, "box_line": [435.4334542016807, 170.37048456057016, 221.22352773109247, 10.61606621140129], "text": "American Patient First Blueprint", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 31, "box_line": [656.649781092437, 170.37048456057016, 11.625928991596652, 10.61606621140129], "text": "\u201d)", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QOJBAA+DejaVuSerif", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 32, "box_line": [676.2208554621849, 170.37048456057016, 322.4289613445378, 10.61606621140129], "text": "that seek to amend pharmaceutical pricing and", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 33, "box_line": [24.738352605042017, 181.59522060570066, 973.9114642016807, 10.616054038004904], "text": "reimbursement practices such as using international pricing indexes, modifying the federal Anti-Kickback statute discount safe harbor, accelerating", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 34, "box_line": [24.738352605042017, 192.81994447743477, 973.9114642016807, 10.616054038004677], "text": "generic drug approval processes, promoting the use of biosimilar drugs and the option of applying step therapy, listing prices of products in DTC", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 35, "box_line": [24.738352605042017, 204.04466834916866, 973.8959083193279, 10.616066211401517], "text": "television advertisements and granting additional authority to governmental agencies to manage drug utilization and negotiate drug prices and", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 36, "box_line": [24.738352605042017, 215.26940439429939, 973.8959083193279, 10.616054038004677], "text": "laws at the state level (including laws that have recently been enacted in California, Vermont, Nevada and New York that are focused on drug", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 37, "box_line": [24.738352605042017, 226.49412826603327, 973.9165116806722, 10.61605403800479], "text": "pricing transparency and/or limiting state spending on drugs), including the proposed rule by the U.S. federal government to allow states or certain", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 38, "box_line": [24.738352605042017, 237.71885213776727, 973.9098793277312, 10.616066211401403], "text": "other non-federal government entities to submit proposals to the FDA allowing for the importation of certain prescription drugs from Canada;", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 39, "box_line": [24.738352605042017, 248.94358818289788, 973.9114642016807, 10.61605403800479], "text": "(iv) the potential impact of changes to U.S. federal pharmaceutical coverage and reimbursement policies and practices, including changes resulting", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 40, "box_line": [24.738352605042017, 260.1683120546319, 973.8968557983194, 10.616054038004677], "text": "from our implementation of the guidance in the 2016 final rule issued by the CMS on the calculation of average manufacturer price and best price", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 41, "box_line": [24.738352605042017, 271.39303592636577, 973.8973726050422, 10.616066211401517], "text": "(which also will require inclusion of sales in U.S. Territories in the calculation of average manufacturer price and best price beginning on April 1,", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 42, "box_line": [24.738352605042017, 282.61538598574816, 973.9114642016807, 10.61844002375301], "text": "2022), as well as the scrutiny of drug manufacturers, including Celgene, by the House Oversight and Reform Committee in January 2019 seeking", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 43, "box_line": [24.738352605042017, 293.8401220308789, 973.9166150420169, 10.618427850356284], "text": "documents and detailed information about drug-pricing practices; (v) reimbursement delays; (vi) government price erosion mechanisms across", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 44, "box_line": [24.738352605042017, 305.0648459026129, 973.9111541176471, 10.616054038004677], "text": "Europe and in other countries resulting in deflation for pharmaceutical product pricing; (vii) the increased purchasing power of entities that", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 45, "box_line": [24.738352605042017, 316.2895697743468, 973.9027301680674, 10.616066211401517], "text": "negotiate on behalf of Medicare, Medicaid and private sector beneficiaries; (viii) collection delays or failures to pay in government-funded public", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 46, "box_line": [24.738352605042017, 327.5143058194775, 973.8897066386555, 10.616054038004677], "text": "hospitals outside the U.S.; (ix) the impact on pricing from parallel trade and drug importation across borders; (x) other developments in technology", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 47, "box_line": [24.738352605042017, 338.7390296912114, 973.9173557983194, 10.616054038004904], "text": "and/or industry practices that could impact the reimbursement policies and practices of third-party payers; and (xi) inhibited market access due to", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 48, "box_line": [24.738352605042017, 349.9637535629455, 973.9011625210086, 10.616054038004677], "text": "real or perceived differences in value propositions for our products compared to competing products. We expect that these market access", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 49, "box_line": [24.738352605042017, 361.1884774346794, 973.9111541176471, 10.616066211401403], "text": "constraints, pharmaceutical pricing controls and discounting and other restrictions will become more acute and will continue to negatively affect", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053842, "box": [24.738352605042017, 58.12320932304044, 973.9173557983194, 324.90605819477435], "id_box_line": 50, "box_line": [24.738352605042017, 372.41321347981, 260.51708016806725, 10.61605403800479], "text": "our future revenues and profit margins.", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053843, "box": [24.738352605042017, 394.8626612232779, 973.9124116806724, 100.41388153206651], "id_box_line": 51, "box_line": [24.738352605042017, 394.8626612232779, 973.905159159664, 10.616066211401517], "text": "Additionally, in early 2016, Health Resources and Services Administration (\u201cHRSA\u201d) finalized a regulation regarding the 340B pricing methodology", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053843, "box": [24.738352605042017, 394.8626612232779, 973.9124116806724, 100.41388153206651], "id_box_line": 52, "box_line": [24.738352605042017, 406.0873972684086, 973.8959083193279, 10.61605403800479], "text": "and providing guidelines for when civil monetary penalties may be issued for \u201cknowing and intentional\u201d manufacturer overcharges of 340B covered", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053843, "box": [24.738352605042017, 394.8626612232779, 973.9124116806724, 100.41388153206651], "id_box_line": 53, "box_line": [24.738352605042017, 417.3121211401426, 973.8959083193279, 10.616054038004677], "text": "entities. The effective date of this regulation was January 1, 2019. Following the effective date, manufacturers who are found to have knowingly and", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053843, "box": [24.738352605042017, 394.8626612232779, 973.9124116806724, 100.41388153206651], "id_box_line": 54, "box_line": [24.738352605042017, 428.5368450118765, 973.9124116806724, 10.616066211401403], "text": "intentionally overcharged 340B covered entities could be subject to significant monetary penalties. Such findings could also result in negative", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053843, "box": [24.738352605042017, 394.8626612232779, 973.9124116806724, 100.41388153206651], "id_box_line": 55, "box_line": [24.738352605042017, 439.7615810570071, 973.9114642016807, 10.61605403800479], "text": "publicity that could harm the manufacturer\u2019s reputation or cause business disruption. Over the course of the past few years, Celgene had received", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053843, "box": [24.738352605042017, 394.8626612232779, 973.9124116806724, 100.41388153206651], "id_box_line": 56, "box_line": [24.738352605042017, 450.9863049287411, 973.9124116806724, 10.61605403800479], "text": "inquiries from HRSA regarding the limited distribution networks for Revlimid, Pomalyst, and Thalomid and compliance with the 340B program. We", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053843, "box": [24.738352605042017, 394.8626612232779, 973.9124116806724, 100.41388153206651], "id_box_line": 57, "box_line": [24.738352605042017, 462.2110288004751, 973.8959083193279, 10.616066211401403], "text": "believe that we have complied with applicable legal requirements. If we are ultimately required to change our sales or pricing practices with regard", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053843, "box": [24.738352605042017, 394.8626612232779, 973.9124116806724, 100.41388153206651], "id_box_line": 58, "box_line": [24.738352605042017, 473.4357648456057, 973.9124116806724, 10.61605403800479], "text": "to the distribution of these drugs under the 340B program, or if we were required to pay penalties under the applicable regulations, there would be", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053843, "box": [24.738352605042017, 394.8626612232779, 973.9124116806724, 100.41388153206651], "id_box_line": 59, "box_line": [24.738352605042017, 484.6604887173397, 336.3086121008404, 10.616054038004677], "text": "an adverse effect on our revenues and profitability.", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053844, "box": [24.738352605042017, 518.3346725059382, 973.9165116806722, 55.51496169833729], "id_box_line": 61, "box_line": [24.738352605042017, 518.3346725059382, 973.9165116806722, 10.616054038004734], "text": "Compounds or products may appear promising in development but fail to reach market within the expected or optimal timeframe, or at all. In", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053844, "box": [24.738352605042017, 518.3346725059382, 973.9165116806722, 55.51496169833729], "id_box_line": 62, "box_line": [24.738352605042017, 529.5593963776722, 973.9011625210086, 10.616066211401403], "text": "addition, product extensions or additional indications may not be approved. Furthermore, products or indications approved under the U.S. FDA's", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053844, "box": [24.738352605042017, 518.3346725059382, 973.9165116806722, 55.51496169833729], "id_box_line": 63, "box_line": [24.738352605042017, 540.7841324228029, 973.8897066386555, 10.616054038004734], "text": "Accelerated Approval Program may be contingent upon verification and description of clinical benefit in confirmatory studies and such studies may", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053844, "box": [24.738352605042017, 518.3346725059382, 973.9165116806722, 55.51496169833729], "id_box_line": 64, "box_line": [24.738352605042017, 552.0064703087886, 973.9014726050422, 10.618440023752953], "text": "not be successful. For example, in July 2019, we announced that Part 2 of the Phase III CheckMate-227 trial did not meet its primary endpoint of", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053844, "box": [24.738352605042017, 518.3346725059382, 973.9165116806722, 55.51496169833729], "id_box_line": 65, "box_line": [24.738352605042017, 563.2312063539193, 832.6608482352942, 10.618427850356284], "text": "overall survival with Opdivo plus chemotherapy versus chemotherapy therapy in patients with first-line non-squamous NSCLC.", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053845, "box": [24.738352605042017, 585.6806540973871, 973.9129457142857, 66.73969774346801], "id_box_line": 66, "box_line": [24.738352605042017, 585.6806540973871, 973.9129457142857, 10.61606621140146], "text": "Developing and commercializing new compounds and products involve inherent risks and uncertainties, including (i) efficacy and safety concerns,", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053845, "box": [24.738352605042017, 585.6806540973871, 973.9129457142857, 66.73969774346801], "id_box_line": 67, "box_line": [24.738352605042017, 596.9053901425178, 973.8968557983194, 10.61605403800479], "text": "delayed or denied regulatory approvals, delays or challenges with producing products on a commercial scale or excessive costs to manufacture", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053845, "box": [24.738352605042017, 585.6806540973871, 973.9129457142857, 66.73969774346801], "id_box_line": 68, "box_line": [24.738352605042017, 608.1301140142518, 973.9124116806724, 10.616054038004677], "text": "products; (ii) inability to enroll patients and timely completion of the clinical trials; (iii) failure to enter into or implement optimal alliances for the", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053845, "box": [24.738352605042017, 585.6806540973871, 973.9129457142857, 66.73969774346801], "id_box_line": 69, "box_line": [24.738352605042017, 619.3548378859857, 973.8944268067228, 10.61606621140146], "text": "development and/or commercialization of new products; (iv) failure to maintain a consistent scope and variety of promising late-stage products;", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053845, "box": [24.738352605042017, 585.6806540973871, 973.9129457142857, 66.73969774346801], "id_box_line": 70, "box_line": [24.738352605042017, 630.5795739311163, 12.411526890756306, 10.61605403800479], "text": "(v)", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053845, "box": [24.738352605042017, 585.6806540973871, 973.9129457142857, 66.73969774346801], "id_box_line": 71, "box_line": [41.24826189075631, 630.5795739311163, 957.4025023949581, 10.61605403800479], "text": "failure of one or more of our products to achieve or maintain commercial viability; and (vi) changes in regulatory approval processes may cause", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053845, "box": [24.738352605042017, 585.6806540973871, 973.9129457142857, 66.73969774346801], "id_box_line": 72, "box_line": [24.738352605042017, 641.8042978028504, 285.36726630252105, 10.61605403800479], "text": "delays or denials of new product approvals.", "category": "Text", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QUJBAA+DejaVuSerif-Italic", "size": 13}}, {"id_box": 1053846, "box": [24.738352605042017, 507.010078087886, 730.3432121008403, 10.71592458432309], "id_box_line": 60, "box_line": [24.738352605042017, 507.010078087886, 730.3432121008403, 10.71592458432309], "text": "We may experience difficulties or delays in the development and commercialization of new products.", "category": "Section-header", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QIJBAA+DejaVuSerif-BoldItalic", "size": 13}}, {"id_box": 1053847, "box": [503.484530672269, 676.1798761876485, 16.414022689075637, 10.616054038004734], "id_box_line": 73, "box_line": [503.484530672269, 676.1798761876485, 16.414022689075637, 10.616054038004734], "text": "20", "category": "Page-footer", "words": [], "linking": [], "font": {"color": [0, 0, 0, 255], "name": "/QOJBAA+DejaVuSerif", "size": 13}}]}